The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The North America legal cannabis market size reached US$ 20.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 111.9 Billion by 2027, exhibiting a growth rate (CAGR) of 33.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cannabis is a drug derived from the dried leaves and flowers of the hemp plant that grows in the tropical and temperate areas of the world. Also known as hash, weed, marijuana, pot, dope, smoke and cone, cannabis can be obtained in various forms ranging from the simple process of drying and curing marijuana flowers to the sophisticated chemistry of producing cannabis concentrates. In North America, the legal landscape is giving way to the decriminalization and full legalization of cannabis, owing to which it is gaining prominence for both medical and recreational purposes.
In the United States, marijuana has been legalized in 30 states for medicinal use and in 9 states for both therapeutic as well as recreational purposes. In Canada, medicinal usage of the drug has been legalized since 2001; however, its recreational use has been authorized through a bill passed in June 2018. This modification in the regulatory landscape has led to an increase in the usage of medical cannabis for treating several diseases associated with changing lifestyles such as chronic pain, depression, post-traumatic stress disorder, social anxiety, cancer, multiple sclerosis and epilepsy. Also, with the implementation of these stringent regulations, suppliers have to comply with proper safety control measures and provide consumers with high-quality products, which further acts in favor of the growth of the market.
The use of industrial hemp, a product derived from cannabis, has also expanded to a great variety of products, including health foods, organic body care, clothing, construction materials, biofuels and plastic composites. Moreover, increasing research and development (R&D) activities in the medical applications of cannabis are expected to create positive opportunities for both the existing players and new entrants in the upcoming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the North America legal cannabis market report, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on products derived and distribution channel.
Breakup by Products Derived:
Marijuana currently represents the leading segment. It is a greenish-grey mixture of the dried flowers of Cannabis sativa. The applications of marijuana are further divided on the basis of medical and recreational uses. Its therapeutic applications include the treatment of various diseases such as migraine, cancer, arthritis and others.
Breakup by Distribution Channel:
Among these, legal cannabis is mostly distributed through regulatory dispensaries.
Country-wise, the United States enjoys a leading position in the market as the medical use of cannabis has been legalized in 31 states including the territories of Puerto Rico and Guam, and the District of Colombia and in 9 states including California, Nevada, Alaska and Colorado for both medicinal and recreational uses.
The market is highly fragmented with the presence of numerous small and large manufacturers who compete in terms of prices and quality. Some of the leading players operating in the market are:
|Base Year of the Analysis||2021|
|Segment Coverage||Products Derived, Distribution Channel, Region|
|Countries Covered||United States, Canada|
|Companies Covered||22nd Century Group, Inc, Medical Marijuana Inc, Hemp, Inc., Axim Biotechnologies, Inc, Arena Pharmaceuticals, Inc., Canopy Growth Corporation, Aphria Inc., Aurora Cannabis Inc. and Abcann Medicinals Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The North America legal cannabis market was valued at US$ 20.5 Billion in 2021.
We expect the North America legal cannabis market to exhibit a CAGR of 33.2% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to the rising focus on drug discovery and clinical trials for novel vaccines against the coronavirus infection, resulting in the postponement of numerous R&D activities for cannabis-based drugs across North America.
The growing adoption of medical cannabis in combination with other therapies to combat the side-effects and increase the effectiveness of the treatment for various medical ailments, such as chronic pain, cancer, social anxiety, etc., is primarily driving the North America legal cannabis market.
Based on the products derived, the North America legal cannabis market has been segregated into marijuana and industrial hemp, where marijuana currently holds the largest market share.
Based on the distribution channel, the North America legal cannabis market can be bifurcated into regulated dispensary, recreational stores, stand-alone retailers, and others. Currently, regulated dispensary exhibits a clear dominance in the market.
On a regional level, the market has been classified into United States and Canada, where the United States currently dominates the North America legal cannabis market.
Some of the major players in the North America legal cannabis market include 22nd Century Group, Inc, Medical Marijuana Inc, Hemp, Inc., Axim Biotechnologies, Inc., Arena Pharmaceuticals, Inc., Canopy Growth Corporation, Aphria Inc., Aurora Cannabis Inc., Abcann Medicinals Inc, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at